Context Therapeutics Inc. Operating Income Loss

• Context Therapeutics Inc. showed a decrease of -32.7% in Operating Income Loss from 2024 to 2025.
• This data is from Context Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Context Therapeutics Inc.'s Operating Income Loss has declined by 1,443.5%.
• Historical annual values: Fiscal year 2025: -$39.70 million | Fiscal year 2024: -$29.92 million | Fiscal year 2023: -$25.07 million | Fiscal year 2022: -$15.38 million | Fiscal year 2021: -$10.53 million | Fiscal year 2020: -$2.57 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026